Prevalence of Pathogens in Synovial Fluid Obtained From Emergency Department Patients and Clinical and Laboratory Features of Patients Diagnosed With Septic Arthritis

Trial Information
Status: Recruiting
Location: See location...
Study Type: Observational

This is a prospective, observational study of patients presenting to the emergency departments at 9 EMERGEncy ID NET sites. The objectives of the proposed study are to: Describe the range and proportion of infectious agents in synovial fluid as detected by standard C&S and investigational PCR testing, i.e., Biofire® Film Array® Bone and Joint Infection (BJI) Panel, Describe the epidemiology of patients receiving diagnostic arthrocentesis and those diagnosed with septic arthritis in the emergency department (ED), Determine the prevalence of septic arthritis in US ED patients presenting with an atraumatic painful swollen joint, and Determine the clinical (history and physical examination) and laboratory characteristics of septic arthritis. Study coordinators screen the ED log for adult patients presenting with joint pain and whose treating physician ordered an arthrocentesis. After confirming eligibility, study coordinators approach the patient to explain the study, and present the written consent form. If the patient agrees to participate and consent, the study coordinator completes an enrollment data collection using patient and treating physician interview to gather responses. After enrollment, the study coordinator will ensure that approximately 0.3-1.0 mL of leftover synovial fluid is saved and stored in a freezer for shipment to a central laboratory (Truman Medical Center hospital laboratory, Kansas City, MO) for testing. Approximately 30 days after enrollment, study coordinators complete an electronic medical record (EMR) review.

Am I eligible for this trial?
Participation Requirements
Minimum Age:
Healthy Volunteers:

• Age 18 years and older;

• diagnostic arthrocentesis in the emergency department (ED) or during hospitalization if admitted from the ED;

• arthrocentesis and joint culture ordered; and

• provide written consent in English or Spanish

Where is this trial taking place?
United States
Olive View-UCLA Medical Center
Who do I contact about this trial?
Greg Moran, MD
When is this trial taking place?
Start Date: September 1, 2021
Estimated Completion Date: December 31, 2023
How many participants will be in this trial?
Target number of participants: 500

This content was sourced from